The incidence of invasive fungal infections
|
|
- Stewart Phillips
- 6 years ago
- Views:
Transcription
1 AN EPIDEMIOLOGIC UPDATE ON INVASIVE FUNGAL INFECTIONS * Michael A. Pfaller, MD ABSTRACT *Based on a presentation given by Dr Pfaller at a symposium held in conjunction with the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Professor of Pathology, Director, Molecular Epidemiology and Fungus Testing Laboratory, Division of Medical Microbiology, Department of Pathology, University of Iowa College of Medicine, Iowa City, Iowa. Address correspondence to: Michael A. Pfaller, MD, Department of Pathology, Medical Microbiology Division, University of Iowa College of Medicine, 200 Hawkins Drive, Room C606GH, Iowa City, IA michael-pfaller@uiowa.edu. Aspergillus and Candida are the 2 major sources of invasive mycoses, and deaths due to these infections have been increasing overall during the past 2 decades. Antimicrobial resistance is an important concern, but the extent of resistance among fungi remains largely undefined. Assessing resistance patterns is essential to determine optimal treatment strategies. For invasive Candida infections, the echinocandins and broad-spectrum triazoles are more potent than fluconazole and amphotericin B against significant clinical isolates of Candida, including the increasing number of fluconazole-resistant isolates (ie, C glabrata and C krusei). For invasive aspergillosis, 2 new approaches have the potential to improve on the hitherto abysmal mortality figures. Voriconazole has potent activity against Aspergillus and appears to be fungicidal, at least in neutropenic rabbit models of invasive aspergillosis. Voriconazole is active against all Aspergillus species and has been shown to be superior to amphotericin B in clinical trials of invasive aspergillosis. Caspofungin treatment of Aspergillus results in decreased angioinvasion and decreased pulmonary infarcts in animal models of invasive aspergillosis. However, its use as a primary therapy or as combination therapy is an outstanding question that still remains to be answered. To correlate in vitro and in vivo data, we suggest the rule : (bacterial or fungal) infections due to susceptible isolates respond to appropriate therapy about 90% of the time, and infections due to resistant isolates or those treated with inappropriate antimicrobials respond about 60% of the time. Our recommendations involve a stepwise approach to using in vitro susceptibility data for selection of fungal therapy. (Adv Stud Med. 2004;4(4A):S269-S275) The incidence of invasive fungal infections is increasing for several reasons: the increase in the number of patients at risk for developing these infections due to advances in chemotherapy regimens, increased use of high-dose corticosteroids, advances in solid-organ and bone marrow transplantation, and increased immunosuppression due to other infections. 1 Many of these factors prolong the survival of critically ill patients and increase the number of susceptible patients. A recent analysis of the National Center for Health Statistics database for multiple causes of death found that deaths due to mycoses increased from the tenth to the seventh most common cause between 1980 and During this same time period, the number of deaths due to invasive mycoses (based on death certificate data) increased from 1557 to 6534, which translates to a 3.4-fold rate increase, or from 0.7 to 2.4 deaths per in the general population. Given that only the information on the death certificate was available, these are almost surely underestimates from the failure to clinically diagnose mycotic infection in severely ill patients. 2 Advanced Studies in Medicine S269
2 The 2 major sources of fungal infections are Aspergillus and Candida. Deaths due to candidiasis have decreased dramatically from their peak during the study period, 2 but the majority of the deaths were in non- HIV infected patients. This downward trend is most likely, therefore, due to decreases in candidemia and invasive candidiasis, rather than the more characteristic Candida infections in HIV-associated disease (ie, oropharyngeal candidiasis and esophagitis). Of note, non-albicans Candida is emerging among high-risk patients, 2 the ramifications of which will be discussed in this article. Antimicrobial resistance is an important concern for mycoses as well as bacterial and viral infections, but the extent of the resistance problems among fungi remain largely undefined. Yet, it is critical to assess resistance patterns to determine optimal treatment strategies in these fragile patients. Resistance occurs through innate and acquired mechanisms in yeasts and molds. Table 1 lists the current and pending antifungal treatments and a brief description of their mechanisms of action. 1 49% in 2001, with no significant increase in crude mortality. 8,9 Of note, the patients with candidemia in the earlier study period were primarily neutropenic, whereas in the later period, almost all of the candidemia infections were in nonneutropenic patients (ie, mostly intensive care unit [ICU] patients). 8,9 The patient population becoming infected in 2001 was actually less sick overall than the population from 1986, so the impact of infection was even greater. The top 5 causative species for candidemia are Candida albicans, C glabrata, C parapsilosis, C tropicalis, and C krusei. Fluconazole is used extensively in the treatment of candidal infections. Resistance to fluconazole is now well documented in AIDS and patients with oropharyngeal candidiasis, but remains uncommon among bloodstream infections, with the exception of C glabrata and C krusei. C albicans, C tropicalis, and C parapsilosis remain very susceptible (97%, 98%, and 99% susceptible, respectively) to fluconazole, assuming a breakpoint of 8 µg/ml. 10 C glabrata is the second most common species in the United States, yet it is only 60% CANDIDA Candidemia is arguably the most important of the invasive mycoses. Occurrence varies based on the study population but ranges from 0.5 to 10 per 1000 hospital admissions and 6 to 10 episodes per in the general population. Candida accounts for 8% to 10% of all nosocomial bloodstream infections. 3-7 As noted earlier, until 1997, the mortality due to candidemia had been decreasing. However, at the University of Iowa, case-controlled studies in 2 separate time periods ( and ) show that the excess mortality due to candidemia is actually increasing. In these studies, case patients were closely matched with control patients during the same time period according to age, sex, date of hospital admission, underlying disease(s), length of time at risk, and surgical procedure(s). The results show that the excess attributable mortality between the 2 groups increased from 38% in 1986 to Table 1. Selected Systemic Antifungal Agents Drug Formulation Mechanism of action Binds to ergosterol, the major sterol Amphotericin B deoxycholate IV in fungal cytoplasmic membranes; Amphotericin B binding creates channels, thus increasing lipid complex IV permeability and causing death Amphotericin B through leakage of essential nutrients colloidal dispersion IV Liposomal amphotericin B IV POLYENE Inhibits fungal cytochrome P45014DM Itraconazole Oral, IV (lanosterol 14-alpha-demethylase, which Voriconazole Oral, IV catalyzes a late step in ergosterol biosynthesis); Posaconazole* Oral precursors to ergosterol therefore accumulate, Ravuconazole* Oral resulting in abnormalities in membrane permeability, membrane-bound enzyme activity, and coordination of chitin synthesis TRIAZOLE Interferes with cell wall biosynthesis by Caspofungin IV noncompetitive inhibition of 1,3-beta-D- Anidulafungin* IV glucan synthase; 1,3-beta-D-glucan is an Micafungin* IV essential cell wall polysaccharide ECHINOCANDIN IV = intravenous. *Under investigation for US Food and Drug Administration approval. Adapted with permission from Steinbach WJ, Stevens DA. Review of newer antifungal and immunomodulatory strategies for invasive aspergillosis. Clin Infect Dis. 2003;37(suppl 3):S157-S The Infectious Disease Society of America. S270 Vol. 4 (4A) April 2004
3 susceptible, and 7% are highly resistant. C glabrata infections treated with fluconazole must have optimal dosing for efficacy. Of note, C krusei does not respond adequately (5% susceptible) to fluconazole and so it should be considered universally resistant to this drug. 10 There has been a notable increase in bloodstream infections with C glabrata in the last half of the 1990s This is due in part to suboptimal dosing of fluconazole (ie, <400 mg per day) and for poor indications (eg, in a surgical ICU, using fluconazole 100 mg daily for poorly defined indications). 16 Suboptimal dosing has important consequences beyond poor outcome. By first exposing the Candida species in the gut flora to fluconazole, strains with decreased susceptibility will naturally be selected (ie, C glabrata). Subinhibitory concentrations of fluconazole in these species will induce CDR efflux pumps, which render the fungus not only fluconazole resistant but also panazole resistant. For this reason, C glabrata should be the focus of surveillance efforts. Amphotericin B has historically been considered to be the gold standard for treating Candida infections, but its antifungal activity is species dependent. Using the Etest method of susceptibility testing, the differences among C albicans, C glabrata, and C krusei become apparent (Table 2). 10 Using 1 µg/ml as a point of comparison, resistance to amphotericin B by C glabrata is significantly increased. As supported by the Infectious Diseases Society of America recommendations for treating candidiasis, breakthrough fungemias occur more often with C glabrata and C krusei when standard doses of amphotericin B are used. Doses clearly need to be higher for effective treatment, but the optimal dose is not yet known, and the effect of different formulations of amphotericin B and dosing has also not been studied. 17 Voriconazole is one of the newer triazoles, although it has not yet been approved for use in treating Candida. In analyzing more than 6200 bloodstream isolates of Candida, and stratifying them by susceptibility to fluconazole, it appears that voriconazole as well as ravuconazole are potent antifungal agents against fluconazole-susceptible isolates; 10 their potency extends to more than 90% susceptibility at 1 µg/ml, which is a concentration that can easily be achieved or exceeded with current dosing regimens. Approximately half of the fluconazole-resistant Candida species will have low minimum inhibitory concentrations (MICs) to these new triazoles, which is essentially accounted for by C krusei. Notably, 98% to 100% of C krusei isolates were susceptible to ravuconazole or voriconazole (MIC 1 µg/ml), irrespective of their level of resistance to fluconazole. In fact, Table 2. Susceptibility to Amphotericin B Across Select Candida Species Cumulative % inhibited at MIC*: Species (n tested) C albicans >99 >99 >99 (3727) C glabrata (796) C krusei (106) *By Etest method. MIC = minimum inhibitory concentration. Adapted with permission from the American Society for Microbiology. Pfaller MA, Messer SA, Hollis RJ, Jones RN, Diekema DJ. In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp. Antimicrob Agents Chemother. 2002;46(6): Table 3. Caspofungin Has Excellent In Vitro Activity Against Candida % Susceptible at MIC (µg/ml) of: Candida Species C albicans C glabrata C parapsilosis C tropicalis C dubliniensis C krusei C lusitaniae N = Overall MIC 90 = 1 µg/ml. MIC = minimum inhibitory concentration. Adapted with permission from the American Society for Microbiology. Pfaller MA, Diekema DJ, Messer SA, Hollis RJ, Jones RN. In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp, including 157 fluconazole-resistant isolates. Antimicrob Agents Chemother. 2003;47(3): Advanced Studies in Medicine S271
4 of the 4 triazoles tested in this study (including fluconazole and itraconazole), only ravuconazole and voriconazole were reliably active against C krusei, indicating a wider spectrum of protection with these newer agents. The other half that remain nonsusceptible to the other triazoles are due to panazole resistance by fluconazole-resistant C glabrata. 10 Caspofungin has broad-spectrum activity against both Candida and Aspergillus infections and has recently received US Food and Drug Administration (FDA) approval for treating Candida bloodstream infection, esophageal candidiasis, and certain other Candida infections, as well as salvage therapy for aspergillosis. Analysis of nearly 4000 isolates of Candida species obtained from more than 95 different medical centers worldwide show that this drug is a potent antifungal agent, maintaining strong activity in fluconazole-resistant isolates. As shown in Table 3, almost all isolates exhibit 95% or greater susceptibility to caspofungin at an MIC of 1 µg/ml. 18 C parapsilosis has a somewhat lower susceptibility in vitro but responds to caspofungin in vivo. 19 Caspofungin also exhibits potency in fluconazole-resistant strains, with more than 90% susceptibility at 1 µg/ml (Table 4), so infections involving fluconazole-resistant C glabrata can be treated by this broad-spectrum agent. 18 The pharamacokinetics and pharmacodynamics of caspofungin for Candida infections is fairly well documented. Peak concentrations can be achieved in excess of 16 µg/ml with the recommended dose of 1 mg/kg per day. There is concentration-dependent killing with caspofungin with the optimal peak-to-mic ratio of about 4:1. Given the MIC data discussed above, this can be achieved for virtually all of the Candida species. Also, there is a post-antifungal effect of more than 12 hours with caspofungin. 20,21 For invasive Candida infections, the echinocandins and broad-spectrum triazoles are more potent than fluconazole and amphotericin B against significant clinical isolates of Candida (ie, C glabrata and C krusei). In particular, the in vivo data support the in vitro data regarding the efficacy of the echinocandins in the treatment of invasive candidiasis, including among the increasing number of fluconazole-resistant isolates. ASPERGILLUS Aspergillosis is also a devastating infection. Case fatality rates associated with invasive aspergillosis Table 4.Antifungal Susceptibility of Candida Species to Caspofungin by Fluconazole Susceptibility Cumulative % Inhibited at MIC (µg/ml) of: Fluconazole Tested Susceptibility (n) Susceptible Susceptibility Dose-Dependent Resistant MIC = minimum inhibitory concentration. Adapted with permission from the American Society for Microbiology. Pfaller MA, Diekema DJ, Messer SA, Hollis RJ, Jones RN. In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp, including 157 fluconazole-resistant isolates. Antimicrob Agents Chemother. 2003;47(3): Table 5. Species of Aspergillus Isolated from Hospitalized Patients with Signs and Symptoms of Pneumonia: SENTRY Objective F, Species n %* A fumigatus A flavus A niger A versicolor A terreus Other species *% of 382 total isolates Data from Diekema et al. 23 Table 6. In Vitro Susceptibilities of Aspergillus Species to Established and Investigational Agents Agent MIC 90 1 µg/ml (%) Caspofungin (MEC) Posaconazole Voriconazole Ravuconazole Amphotericin B Itraconazole N = 382: A fumigatus (n = 257); A flavus (n = 30); A niger (n = 29); A versicolor (n = 21); A terreus (n = 16), other Aspergillus (n = 29). MEC = minimum effective concentration. Data from Diekema et al. 23 S272 Vol. 4 (4A) April 2004
5 hover at 60%, increasing up to 87% in bone marrow transplant recipients. 22 Even with the use of amphotericin B deoxycholate and its lipid formulations, preventing mortality was achieved in only one third to one half of patients. 22 Approximately 5 species of Aspergillus are found in hospitalized patients with signs and symptoms of pneumonia, the most common of which is A fumigatus (Table 5). 23 However, as with Candida, some of the less common species cause the most concern because of their susceptibility patterns to commonly used antifungal agents. Of particular concern is A terreus. Again using 1 µg/ml as a point of comparison (because this dose can be exceeded by the dosing practices for all of the drugs tested), all of the newer agents are active against Aspergillus spp (Table 6). 23 These data include A terreus, and as shown in Table 7, susceptibility to A terreus is 100% for all agents except amphotericin B, for which almost two thirds of A terreus isolates have MICs of 2 µg/ml or higher. 23 Echinocandins inhibit growth by inhibiting glucan synthesis at growing hyphal tips and branch points. They do not kill the entire mold, so the rest of the hyphal mass may remain viable and appear as trailing growth. To assess the in vitro efficacy of caspofungin against Aspergillus, the microscopic morphology of the organism needs to be observed. As such, efficacy is measured by the minimum effective concentration (MEC), which is the first concentration at which a prominent visual change in the growth pattern and, microscopically, a transition from healthy organisms to sick aberrant forms is observed. Data for the in vitro activity of echinocandins against molds are often referred to as MEC, rather than MIC, indicating this unique fungistatic activity. Caspofungin treatment of Aspergillus results in decreased angioinvasion and decreased pulmonary infarcts in animal models of invasive aspergillosis. However, its use as a primary therapy or as combination therapy is a question that remains to be answered. Voriconazole has potent activity against Aspergillus and appears to be fungicidal, at least in neutropenic rabbit models of invasive aspergillosis. 24 Voriconazole is active against all Aspergillus species and has been shown to be superior to amphotericin B in clinical trials of invasive aspergillosis. 25 These 2 new approaches to invasive aspergillosis have potential to improve the hitherto abysmal mortality figures. ANTIMICROBIAL SUSCEPTIBILITY TESTING: CORRELATING IN VITRO AND IN VIVO DATA Infectious disease specialists have an imperfect means of determining the extent to which organisms will respond clinically based on laboratory susceptibility testing. We published a review of studies to determine the expected correlation between in vitro and in vivo data. According to the rule, (bacterial or fungal) infections due to susceptible isolates respond to appropriate therapy about 90% of the time, and infections due to resistant isolates or those treated with inappropriate antimicrobials respond about 60% of Table 7. In Vitro Susceptibilities of Aspergillus terreus (n = 16) to Established and Investigational Agents MIC/MEC (µg/ml), % Agent µg/ml Amphotericin B Caspofungin Itraconazole Posaconazole Ravuconazole Voriconazole MIC = minimum inhibitory concentration; MEC = minimum effective concentration. Data from Diekema et al. 23 Table 8.The Rule : Correlation of Susceptibility Testing with Outcome for Fungal and Bacterial Infections Cases with Successful Outcome by Susceptibility Class,* % (n/total) Studies Patients (n) (n) Susceptible Resistant P value Fungi (828/923) 48 (121/274) <.001 Bacteria (4521/5081) 59 (215/366) <.001 *Antifungal testing performed according to NCCLS M27-A2. Includes mucosal, fungemia, meningitis, and disseminated infections due to Candida, C neoformans, and Histoplasma capsulatum treated with fluconazole, itraconazole, or ketoconazole. Data from Rex et al. 26 Advanced Studies in Medicine S273
6 the time. 26 A summary of this review, shown in Table 8, illustrates this rule. While it is not strictly followed, it does show that drug susceptibility test results can be used to guide therapy choices. RECOMMENDATIONS Our recommendations (see Sidebar, below) use a stepwise approach to using in vitro data for selection of fungal therapy. 26 First, it is important to identify the isolate to species. For Candida species from sterile sites, we recommend that routine testing should be done for fluconazole in particular (especially for C glabrata), and possibly for 5-fluorocytosine as well. The susceptibility of species other than C glabrata to fluconazole can be predicted based on previously published data. 10 For Candida species at mucosal sites, routine testing is not necessary, but susceptibility testing to fluconazole and itraconazole are useful for sorting out microbial resistance versus drug-delivery problems with a suboptimal response. We also recommend testing organism drug combinations as an adjunct in patients who fail initial therapy. Candida species, in particular, should be tested against amphotericin B, and Cryptococcus neoformans should be tested against fluconazole, 5-fluorocytosine, or amphotericin because some treatment failures have been associated with the development of drug resistance. There are limited data on Histoplasmosis capsulatum suggesting that fluconazole use may lead to resistance. 27,28 Organisms with a high rate of intrinsic resistance need not be tested; an alternative agent should automatically be selected based on the published literature. Organisms with significant rates of acquired resistance should be monitored closely for treatment failure, and susceptibility testing should be performed if possible. Species with high rates of resistance are listed in Table 9. CONCLUSION The spectrum of predominant yeasts and molds is changing, but several new broad-spectrum antifungal agents have become available, and several apparently are on the brink of FDA approval. Future concerns for invasive fungal infections are moving away from C albicans and A fumigatus, the strains historically most notorious for fatality. Drug resistance, including multidrug resistance, is apparent in some of the emerging Table 9. Species with High Rates of Resistance to Antifungal Agents Drugs (to which there is a high frequency Fungus of resistance) Class of Resistance Aspergillus terreus Amphotericin B Intrinsic Candida glabrata Azoles Intrinsic and acquired Amphotericin B Acquired C krusei Fluconazole Intrinsic 5-fluorocytosine Intrinsic Amphotericin B Acquired C lusitaniae Amphotericin B Intrinsic and acquired Histoplasma capsulatum Fluconazole Acquired Scedosporium apiospermum Amphotericin B Intrinsic S prolificans Amphotericin B Intrinsic Trichosporon beigelii Amphotericin B Intrinsic A Stepwise Approach to the Use of Fungal Identification and Antifungal Susceptibility Testing in the Selection of Antifungal Therapy 1. Identify isolate to species level 2. Candida spp from sterile sites test routinely fluconazole 5-fluorocytosine 3. Candida spp from mucosal sites Routine testing not necessary Test fluconazole and itraconazole to sort out microbial resistance vs drug-delivery problems 4. Test selected organism/drug combinations as an adjunct in patients failing initial therapy Candida spp and amphotericin B (Etest) C neoformans and fluconazole, 5-fluorocytosine, or amphotericin B (Etest) Histoplasma capsulatum and fluconazole 5. Isolates of species with high rates of intrinsic resistance need not be tested Alternative agent 6. Isolates of species with significant rates of acquired resistance Monitor closely for failure Perform susceptibility testing if possible Data from Rex et al. 26 S274 Vol. 4 (4A) April 2004
7 opportunistic molds, as it is with bacteria. Much can be learned from taking the time for susceptibility testing, as long as the clinician understands the limitations of the information provided by tests (ie, the rule ). REFERENCES 1. Steinbach WJ, Stevens DA. Review of newer antifungal and immunomodulatory strategies for invasive aspergillosis. Clin Infect Dis. 2003;37(suppl 3):S157-S McNeil MM, Nash SL, Hajjeh RA, et al. Trends in mortality due to invasive mycotic diseases in the United States, Clin Infect Dis. 2001;33(5): Eggimann P, Garbino J, Pittet D. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis. 2003;3(11): Pfaller MA, Diekema DJ. Role of sentinel surveillance of candidemia: trends in species distribution and antifungal susceptibility. J Clin Microbiol. 2002;40(10): Diekema DJ, Messer SA, Brueggemann AB, et al. Epidemiology of candidemia: 3-year results from the Emerging Infections and the Epidemiology of Iowa Organisms Study. J Clin Microbiol. 2002;40(4): Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis. 1999;29(2): Kao AS, Brandt ME, Pruitt WR, et al. The epidemiology of candidemia in two United States cities: results of a population-based active surveillance. Clin Infect Dis. 1999; 29(5): Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP. Hospital-acquired candidemia: the attributable mortality and excess length of stay. Arch Intern Med. 1988; 148(12): Gudlaugsson O, Gillespie S, Lee K, et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis. 2003;37(9): Pfaller MA, Messer SA, Hollis RJ, Jones RN, Diekema DJ. In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp. Antimicrob Agents Chemother. 2002;46(6): Marco F, Danes C, Almela M, et al. Trends in frequency and in vitro susceptibilities to antifungal agents, including voriconazole and anidulafungin, of Candida bloodstream isolates. Results from a six-year study ( ). Diagn Microbiol Infect Dis. 2003;46(4): Clark TA, Hajjeh RA. Recent trends in the epidemiology of invasive mycoses. Curr Opin Infect Dis. 2002;15(6): Safdar A, Chaturvedi V, Koll BS, Larone DH, Perlin DS, Armstrong D. Prospective, multicenter surveillance study of Candida glabrata: fluconazole and itraconazole susceptibility profiles in bloodstream, invasive, and colonizing strains and differences between isolates from three urban teaching hospitals in New York City (Candida Susceptibility Trends Study, 1998 to 1999). Antimicrob Agents Chemother. 2002;46(10): Safdar A, van Rhee F, Henslee-Downey JP, Singhal S, Mehta J. Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome. Bone Marrow Transplant. 2001;28(9): Sobel JD. Management of infections caused by Candida glabrata. Curr Infect Dis Rep. 2000;2(5): Berrouane YF, Herwaldt LA, Pfaller MA. Trends in antifungal use and epidemiology of nosocomial yeast infections in a university hospital. J Clin Microbiol. 1999;37(3): Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment of candidiasis. Clin Infect Dis. 2004;38(2): Pfaller MA, Diekema DJ, Messer SA, Hollis RJ, Jones RN. In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp, including 157 fluconazole-resistant isolates. Antimicrob Agents Chemother. 2003;47(3): Colombo AL, Perfect J, DiNubile M, et al. Global distribution and outcomes for Candida species causing invasive candidiasis: results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis. Eur J Clin Microbiol Infect Dis. 2003;22(8): Ernst EJ, Klepser ME, Ernst ME, Messer SA, Pfaller MA. In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods. Diagn Microbiol Infect Dis. 1999; 33(2): Deresinski SC, Stevens DA. Caspofungin. Clin Infect Dis. 2003;36(11): Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis. 2001;32(3): Diekema DJ, Messer SA, Hollis RJ, Pfaller MA. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol. 2003; 41(8): George D, Miniter P, Andriole VT. Efficacy of UK , a new azole antifungal agent, in an experimental model of invasive aspergillosis. Antimicrob Agents Chemother. 1996;40(1): Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347(6): Rex JH, Pfaller MA. Has antifungal susceptibility testing come of age? Clin Infect Dis. 2002;35(8): Wheat J, Marichal P, Vanden Bossche H, Le Monte A, Connolly P. Hypothesis on the mechanism of resistance to fluconazole in Histoplasma capsulatum. Antimicrob Agents Chemother. 1997;41(2): Wheat LJ, Connolly P, Smedema M, Brizendine E, Hafner R. Emergence of resistance to fluconazole as a cause of failure during treatment of histoplasmosis in patients with acquired immunodeficiency disease syndrome. AIDS Clinical Trials Group and the Mycoses Study Group of the National Institute of Allergy and Infectious Diseases. Clin Infect Dis. 2001;33(11): Advanced Studies in Medicine S275
Voriconazole. Voriconazole VRCZ ITCZ
7 7 8 7 8 fluconazole itraconazole in vitro in vivo Candida spp. C. glabrata C. krusei Cryptococcus neoformans in vitro Aspergillus spp. in vitro in vivo Aspergillus fumigatus Candida albicans C. krusei
More informationAntifungal Pharmacodynamics A Strategy to Optimize Efficacy
Antifungal Pharmacodynamics A Strategy to Optimize Efficacy David Andes, MD Associate Professor, Department of Medicine Division of Infectious Diseases Medical Microbiology and Immunology University of
More informationAn Update in the Management of Candidiasis
An Update in the Management of Candidiasis Daniel B. Chastain, Pharm.D., AAHIVP Infectious Diseases Pharmacy Specialist Phoebe Putney Memorial Hospital Adjunct Clinical Assistant Professor UGA College
More informationMANAGEMENT OF HOSPITAL-ACQUIRED FUNGAL INFECTIONS
MANAGEMENT OF HOSPITAL-ACQUIRED FUNGAL INFECTIONS Paul D. Holtom, MD Associate Professor of Medicine and Orthopaedics USC Keck School of Medicine Numbers of Cases of Sepsis in the United States, According
More informationReceived 18 December 2008/Returned for modification 9 February 2009/Accepted 9 April 2009
JOURNAL OF CLINICAL MICROBIOLOGY, June 2009, p. 1942 1946 Vol. 47, No. 6 0095-1137/09/$08.00 0 doi:10.1128/jcm.02434-08 Copyright 2009, American Society for Microbiology. All Rights Reserved. Activity
More informationAntifungal Pharmacotherapy
Interpreting Antifungal Susceptibility Testing: Science or Smoke and Mirrors A. W. F O T H E R G I L L, M A, M B A U N I V E R S I T Y O F T E X A S H E A L T H S C I E N C E C E N T E R S A N A N T O
More information1. Pre-emptive therapy. colonization, colonization, pre-emptive therapy. , ICU colonization. colonization. 2, C. albicans
Jpn. J. Med. Mycol. Vol. 45, 217 221, 2004 ISSN 0916 4804,.,, colonization, pre-emptive therapy. 2, non-albicans Candida., fluconazole.,. Key words: postoperative infection, non-albicans Candida, pre-emptive
More informationIsolates from a Phase 3 Clinical Trial. of Medicine and College of Public Health, Iowa City, Iowa 52242, Wayne, Pennsylvania ,
JCM Accepts, published online ahead of print on 26 May 2010 J. Clin. Microbiol. doi:10.1128/jcm.00806-10 Copyright 2010, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationFungal infections in ICU. Tang Swee Fong Department of Paediatrics Universiti Kebangsaan Malaysia
Fungal infections in ICU Tang Swee Fong Department of Paediatrics Universiti Kebangsaan Malaysia Epidemiology of invasive fungal infections - US +300% Martin GS, et al. N Engl J Med 2003;348:1546-1554
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Voriconazole Effective Date... 3/15/2018 Next Review Date... 3/15/2019 Coverage Policy Number... 4004 Table of Contents Coverage Policy... 1 General Background...
More informationUpdated Guidelines for Management of Candidiasis. Vidya Sankar, DMD, MHS April 6, 2017
Updated Guidelines for Management of Candidiasis Vidya Sankar, DMD, MHS April 6, 2017 Statement of Disclosure I have no actual or potential conflict of interest in relation to this presentation Outline
More informationNationwide survey of treatment for pediatric patients with invasive fungal infections in Japan
J Infect Chemother (2013) 19:946 950 DOI 10.1007/s10156-013-0624-7 ORIGINAL ARTICLE Nationwide survey of treatment for pediatric patients with invasive fungal infections in Japan Masaaki Mori Received:
More informationCURRENT AND NEWER ANTI-FUNGAL THERAPIES- MECHANISMS, INDICATIONS, LIMITATIONS AND PROBLEMS. Dr AMIT RAODEO DM SEMINAR
CURRENT AND NEWER ANTI-FUNGAL THERAPIES- MECHANISMS, INDICATIONS, LIMITATIONS AND PROBLEMS Dr AMIT RAODEO DM SEMINAR Introduction The incidence of invasive fungal infections in critically ill intensive
More informationFungi GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER NUMBER 53: Author Moi Lin Ling, MBBS, FRCPA, CPHQ, MBA
GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER NUMBER 53: Fungi Author Moi Lin Ling, MBBS, FRCPA, CPHQ, MBA Chapter Editor Ziad A. Memish, MD, FRCPC, FACP Cover heading - Topic Outline Topic outline
More informationAntifungal Susceptibility Testing
Infect Dis Clin N Am 20 (2006) 699 709 Antifungal Susceptibility Testing Annette W. Fothergill, MA, MBA, MT(ASCP), CLS(NCA) a, Michael G. Rinaldi, PhD a,b, Deanna A. Sutton, PhD, MT, SM(ASCP), SM, RM(NRM)
More informationMicafungin and Candida spp. Rationale for the EUCAST clinical breakpoints. Version February 2013
Micafungin and Candida spp. Rationale for the EUCAST clinical breakpoints. Version 1.0 5 February 2013 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised
More informationWHICH ANTIFUNGAL AGENT IS THE CHOICE FOR SUSPECTED FUNGAL INFECTIONS?
WHICH ANTIFUNGAL AGENT IS THE CHOICE FOR SUSPECTED FUNGAL INFECTIONS? Assoc. Prof. Dr. Serkan SENER Acibadem University Medical School Department of Emergency Medicine, Istanbul Acibadem Ankara Hospital,
More informationAbout the Editor Gerri S. Hall, Ph.D.
About the Editor Gerri S. Hall, Ph.D. Dr. Hall s professional career has been focused on clinical microbiology: direct clinical activities of various areas such as bacteriology, mycobacteria, STD testing,
More informationTable 1. Antifungal Breakpoints for Candida. 2,3. Agent S SDD or I R. Fluconazole < 8.0 mg/ml mg/ml. > 64 mg/ml.
AUSTRALIAN ANTIFUNGAL SUSCEPTIBILITY DATA 2008-2011 Part 1: The Yeasts In this article, an update of recent changes to the CLSI antifungal standards for susceptibility testing of yeasts is presented. We
More informationUse of Antifungal Drugs in the Year 2006"
Use of Antifungal Drugs in the Year 2006" Jose G. Montoya, MD Associate Professor of Medicine Associate Chief for Clinical Affairs Division of Infectious Diseases Stanford University School of Medicine
More informationADEQUATE ANTIFUNGAL USE FOR BLOODSTREAM INFECTIONS
ADEQUATE ANTIFUNGAL USE FOR BLOODSTREAM INFECTIONS COMMERCIAL RELATIONS DISCLOSURE 2500 9000 15000 Astellas Gilead Sciences Pfizer Inc Expert advice Speaker s bureau Speaker s bureau OUTLINE OF THE PRESENTATION
More informationReceived 12 December 2010/Returned for modification 5 January 2011/Accepted 16 March 2011
JOURNAL OF CLINICAL MICROBIOLOGY, May 2011, p. 1765 1771 Vol. 49, No. 5 0095-1137/11/$12.00 doi:10.1128/jcm.02517-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. Multicenter
More informationAntifungal Resistance in Asia: Mechanisms, Epidemiology, and Consequences
5th MMTN Conference 5-6 November 2016 Bangkok, Thailand 10:20-10:45, 6 Nov, 2016 Antifungal Resistance in Asia: Mechanisms, Epidemiology, and Consequences Yee-Chun Chen, M.D., PhD. Department of Medicine,
More informationNew triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance
For reprint orders, please contact reprints@expert-reviews.com New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance Expert Rev. Anti Infect. Ther. 7(8), 981 998
More informationInterpretive Breakpoints for Fluconazole and Candida Revisited: a Blueprint for the Future of Antifungal Susceptibility Testing
CLINICAL MICROBIOLOGY REVIEWS, Apr. 2006, p. 435 447 Vol. 19, No. 2 0893-8512/06/$08.00 0 doi:10.1128/cmr.19.2.435 447.2006 Copyright 2006, American Society for Microbiology. All Rights Reserved. Interpretive
More informationReceived 26 July 2006/Returned for modification 10 October 2006/Accepted 16 October 2006
JOURNAL OF CLINICAL MICROBIOLOGY, Jan. 2007, p. 70 75 Vol. 45, No. 1 0095-1137/07/$08.00 0 doi:10.1128/jcm.01551-06 Copyright 2007, American Society for Microbiology. All Rights Reserved. Use of Fluconazole
More informationImproving Clinical Outcomes in Fungal Infection Control and Management
Improving Clinical Outcomes in Fungal Infection Control and Management DISCLAIMER The information within this CME/CE activity is for continuing education purposes only, and is not intended to substitute
More informationCandida auris: an Emerging Hospital Infection
National Center for Emerging and Zoonotic Infectious Diseases Candida auris: an Emerging Hospital Infection Paige Armstrong MD MHS Epidemic Intelligence Service Officer Mycotic Diseases Branch Association
More informationAmphotericin B, antifungal susceptibility, bloodstream infections, Candida spp., posaconazole, sus-
ORIGINAL ARTICLE 10.1111/j.1469-0691.2005.01310.x Epidemiology of candidaemia and antifungal susceptibility patterns in an Italian tertiary-care hospital A. Bedini 1, C. Venturelli 2, C. Mussini 1, G.
More informationFungi are eukaryotic With rigid cell walls composed largely of chitin rather than peptidoglycan (a characteristic component of most bacterial cell
Antifungal Drugs Fungal infections (Mycoses) Often chronic in nature. Mycotic infections may be superficial and involve only the skin (cutaneous mycoses extending into the epidermis) Others may penetrate
More informationAntifungal drugs Dr. Raz Muhammed
Antifungal drugs 13. 12. 2018 Dr. Raz Muhammed 2. Flucytosine (5-FC) Is fungistatic Is a synthetic pyrimidine antimetabolite Is often used in combination with amphotericin B in the treatment of systemic
More informationInvasive Fungal Infections in Solid Organ Transplant Recipients
Outlines Epidemiology Candidiasis Aspergillosis Invasive Fungal Infections in Solid Organ Transplant Recipients Hsin-Yun Sun, M.D. Division of Infectious Diseases Department of Internal Medicine National
More informationon December 9, 2018 by guest
JCM Accepts, published online ahead of print on 27 June 2012 J. Clin. Microbiol. doi:10.1128/jcm.00937-12 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 2 Progress in Antifungal
More informationCase Studies in Fungal Infections and Antifungal Therapy
Case Studies in Fungal Infections and Antifungal Therapy Wayne L. Gold MD, FRCPC Annual Meeting of the Canadian Society of Internal Medicine November 4, 2017 Disclosures No financial disclosures or industry
More informationVoriconazole October 2015 Risk Management Plan. Voriconazole
Voriconazole October 2015 VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Invasive aspergillosis (IA) is the most devastating of Aspergillus related diseases, targeting severely
More informationHistorically, amphotericin B deoxycholate
OUR CURRENT UNDERSTANDING OF THERAPIES FOR INVASIVE FUNGAL INFECTIONS * John R. Perfect, MD ABSTRACT This article provides an update on the current state of the art for treating invasive fungal infections,
More informationReceived 4 August 2010/Returned for modification 23 October 2010/Accepted 19 November 2010
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 2011, p. 561 566 Vol. 55, No. 2 0066-4804/11/$12.00 doi:10.1128/aac.01079-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. Candida
More informationAntifungals and current treatment guidelines in pediatrics and neonatology
Dragana Janic Antifungals and current treatment guidelines in pediatrics and neonatology Dragana Janic. University Children`s Hospital, Belgrade, Serbia 10/10/17 Hotel Crowne Plaza, Belgrade, Serbia; www.dtfd.org
More informationUpdate zu EUCAST 2012 Cornelia Lass-Flörl
Update zu EUCAST 2012 Cornelia Lass-Flörl Frühjahrstagung 2012 Paul-Ehrlich-Gesellschaft Sektion Antimykotische Chemotherapie Bonn, 4./5. Mai 2012 Agenda 1. Breakpoints 2. Rationale documents and technical
More informationon December 11, 2018 by guest
JCM Accepts, published online ahead of print on 12 December 2012 J. Clin. Microbiol. doi:10.1128/jcm.03125-12 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 Biographical Feature;
More informationFungal Infection in the ICU: Current Controversies
Fungal Infection in the ICU: Current Controversies Andrew F. Shorr, MD, MPH, FCCP, FACP Washington Hospital Center Georgetown University, Washington, DC Disclosures I have served as a consultant to, researcher/investigator
More informationJapan Antifungal Surveillance Program (1):
183 Japan Antifungal Surveillance Program (1): 2001 2002 1) 1) 2) 3) 4) 5) 6) 7) 8) 9) 10) 11) 12) 1) 1) 2) 3) 4) 5) 6) 7) 8) 9) 10) 11) 12) 16 9 14 16 10 12 2001 6 2002 3 2 11 576 fluconazole (FLCZ),
More informationHow Can We Prevent Invasive Fungal Disease?
How Can We Prevent Invasive Fungal Disease? Chris Kibbler Professor of Medical Microbiology University College London And Royal Free Hospital, London, UK Invasive Aspergillosis 2 - Acquisition Preventive
More informationCurrent Options in Antifungal Pharmacotherapy
Current Options in Antifungal Pharmacotherapy John Mohr, Pharm.D., Melissa Johnson, Pharm.D., Travis Cooper, Pharm.D., James S. Lewis, II, Pharm.D., and Luis Ostrosky-Zeichner, M.D. Infections caused by
More informationAntifungal resistance mechanisms in pathogenic fungi
Antifungal resistance mechanisms in pathogenic fungi Shivaprakash M Rudramurthy Additional Professor, Mycology Division Center of Advanced Research in Medical Mycology, National Culture Collection of Pathogenic
More informationAntifungal susceptibility testing: Which method and when?
Antifungal susceptibility testing: Which method and when? Maiken Cavling Arendrup mad@ssi.dk SSI & Juan Luis Rodriguez Tudela jlrtudela@isciii.es ISCIII Agenda Summary of current standards and selected
More informationNewer Combination Therapies
Newer Combination Therapies William J. Steinbach, MD Associate Professor of Pediatrics, Molecular Genetics & Microbiology Pediatric Infectious Diseases Duke University Medical Center Combination Therapy
More informationNo Evidence As Yet. Georg Maschmeyer. Dept. of Hematology, Oncology & Palliative Care Klinikum Ernst von Bergmann Potsdam, Germany
Is Combined Antifungal Therapy More Efficient than Single Agent Therapy? No Evidence As Yet www.ichs.org Georg Maschmeyer Dept. of Hematology, Oncology & Palliative Care Klinikum Ernst von Bergmann Potsdam,
More informationESCMID Online Lecture Library. by author
What is the best antifungal strategy for severe intra-abdominal infections? Philippe Montravers MD, PhD Anaesthesia and Surgical ICU Bichat Claude Bernard Hospital Assistance Publique Hopitaux de Paris
More informationAntifungal Update. Candida: In Vitro Antifungal Susceptibility Testing
Antifungal Update B. Joseph Guglielmo, Pharm.D. Professor and Chair Department of Clinical Pharmacy School of Pharmacy University of California San Francisco The patient spikes a new fever and 3/3 blood
More informationUse of Antifungals in the Year 2008
Use of Antifungals in the Year 2008 Jose G. Montoya, MD Associate Professor of Medicine Associate Chief for Clinical Affairs Division of Infectious Diseases Stanford University School of Medicine Diagnosis
More informationFKS Mutant Candida glabrata: Risk Factors and Outcomes in Patients With Candidemia
Clinical Infectious Diseases Advance Access published July 9, 2014 MAJOR ARTICLE FKS Mutant Candida glabrata: Risk Factors and Outcomes in Patients With Candidemia Nicholas D. Beyda, 1 Julie John, 1 Abdullah
More informationAntifungals in Invasive Fungal Infections: Antifungals in neutropenic patients
BVIKM-SBIMC La Hulpe, 6 November 2008 Antifungals in Invasive Fungal Infections: Antifungals in neutropenic patients Johan Maertens, MD Acute Leukemia and SCT Unit University Hospital Gasthuisberg Catholic
More informationReceived 31 March 2009/Returned for modification 26 May 2009/Accepted 22 June 2009
JOURNAL OF CLINICAL MICROBIOLOGY, Sept. 2009, p. 2766 2771 Vol. 47, No. 9 0095-1137/09/$08.00 0 doi:10.1128/jcm.00654-09 Copyright 2009, American Society for Microbiology. All Rights Reserved. Comparison
More informationSUSCEPTIBILITY PROFILE OF EMERGING FUNGAL PATHOGENS
SUSCEPTIBILITY PROFILE OF EMERGING FUNGAL PATHOGENS Professor Lia Monica JUNIE, Department of Microbiology, University of Medicine and Pharmacy, Cluj Napoca, Romania The most common fungal pathogens are:
More informationANTIFUNGAL AGENTS. Alison Clode, DVM, DACVO. Port City Veterinary Referral Hospital Portsmouth, New Hampshire
ANTIFUNGAL AGENTS Alison Clode, DVM, DACVO Port City Veterinary Referral Hospital Portsmouth, New Hampshire New England Equine Medical and Surgical Center Dover, New Hampshire Overview Fungal organisms
More informationCurrent options of antifungal therapy in invasive candidiasis
Current options of antifungal therapy in invasive candidiasis Saloua Ladeb Bone Marrow Transplant Center Tunis HAMMAMET 24 th April 2012 DEFINITION One or more positive results on blood culture for Candida
More informationyour lab focus susceptibility testing of yeasts and moulds as well as the clinical implications of in vitro antifungal testing.
626 CE update [microbiology and virology] Antifungal Susceptibility Methods and Their Potential Clinical Relevance Ana Espinel-Ingroff, PhD Medical College of Virginia, Virginia Commonwealth University,
More informationSensitivity of Candida albicans isolates to caspofungin comparison of microdilution method and E-test procedure
Basic research Sensitivity of Candida albicans isolates to caspofungin comparison of microdilution method and E-test procedure Anna Serefko, Anna Malm Department of Pharmaceutical Microbiology, Medical
More informationAntifungal Activity of Voriconazole on Local Isolates: an In-vitro Study
Original Article Philippine Journal of OPHTHALMOLOGY Antifungal Activity of Voriconazole on Local Isolates: an In-vitro Study Karina Q. De Sagun-Bella, MD, 1 Archimedes Lee D. Agahan, MD, 1 Leo DP. Cubillan,
More informationBSI. Candida auris: A globally emerging multidrug-resistant yeast 5/19/2017. First report of C. auris from Japan in 2009
5/9/7 BSI Candida auris: A globally emerging multidrug-resistant yeast Mycotic Diseases Branch DFWED Friday Seminar August 6, 6 National Center for Emerging and Zoonotic Infectious Diseases Division of
More informationANA ESPINEL-INGROFF* Division of Infectious Diseases, Medical College of Virginia, Virginia Commonwealth University, Richmond, Virginia
JOURNAL OF CLINICAL MICROBIOLOGY, Jan. 1998, p. 198 202 Vol. 36, No. 1 0095-1137/98/$04.00 0 Copyright 1998, American Society for Microbiology In Vitro Activity of the New Triazole Voriconazole (UK-109,496)
More informationAntifungal Update 2/22/12. Which is the most appropriate initial empirical therapy in a candidemic patient?
Antifungal Update B. Joseph Guglielmo, Pharm.D. Professor and Chair Department of Clinical Pharmacy School of Pharmacy University of California San Francisco 3/3 blood cultures are positive for an unidentified
More informationResistance epidemiology
ECMM/EFISG symposium: Multidrug resistance in fungi? A formidable foe Resistance epidemiology Ana Alastruey Izquierdo Mycology Reference Lab Spain Instituto de Salud Carlos III Disclousure I have received
More informationComparison of microdilution method and E-test procedure in susceptibility testing of caspofungin against Candida non-albicans species
NEW MICROBIOLOGICA, 31, 257-262, 2008 Comparison of microdilution method and E-test procedure in susceptibility testing of caspofungin against Candida non-albicans species Anna Serefko, Renata Los, Anna
More informationAntifungal Agents - Cresemba (isavuconazonium), Vfend. Prior Authorization Program Summary
Antifungal Agents - Cresemba (isavuconazonium), Noxafil (posaconazole), Vfend (voriconazole) Prior Authorization Program Summary FDA APPROVED INDICATIONS DOSAGE 1,2,14 Drug FDA Indication(s) Dosing Cresemba
More informationItraconazole vs. fluconazole for antifungal prophylaxis in allogeneic stem-cell transplant patients D. J. Winston
REVIEW Itraconazole vs. fluconazole for antifungal prophylaxis in allogeneic stem-cell transplant patients D. J. Winston Division of Hematology-Oncology, Department of Medicine, UCLA Medical Center, Los
More informationClinical Considerations in the Management of Systemic Fungal Infections. Conducted during the 41 st ASHP Midyear Clinical Meeting Anaheim, California
Clinical Considerations in the Management of Systemic Fungal Infections Conducted during the 41 st ASHP Midyear Clinical Meeting Anaheim, California CONTINUING EDUCATION ACCREDITATION The American Society
More informationManagement Strategies For Invasive Mycoses: An MD Anderson Perspective
Management Strategies For Invasive Mycoses: An MD Anderson Perspective Dimitrios P. Kontoyiannis, MD, ScD, FACP, FIDSA Professor of Medicine Director of Mycology Research Program M. D. Anderson Cancer
More information1* 1. Vijaya S. Rajmane, Shivaji T. Mohite
ISSN 2231-4261 ORIGINAL ARTICLE Comparison of the VITEK 2 Yeast Antifungal Susceptibility ing with CLSI Broth Microdilution Reference for ing Four Antifungal Drugs against Candida species Isolated from
More information9/7/2018. Faculty. Overcoming Challenges in the Management of Invasive Fungal Infections. Learning Objectives. Faculty Disclosure
Faculty Overcoming Challenges in the Management of Invasive Fungal James S. Lewis II, PharmD, FIDSA ID Clinical Pharmacy Coordinator Oregon Health and Science University Departments of Pharmacy and Infectious
More informationORIGINAL ARTICLE /j x
ORIGINAL ARTICLE 10.1111/j.1469-0691.2005.01268.x Secular trends in nosocomial candidaemia in non-neutropenic patients in an Italian tertiary hospital R. Luzzati 1,2, B. Allegranzi 1, L. Antozzi 1, L.
More informationAntifungal Stewardship. Önder Ergönül, MD, MPH Koç University, School of Medicine, Istanbul 6 October 2017, ESGAP course, Istanbul
Antifungal Stewardship Önder Ergönül, MD, MPH Koç University, School of Medicine, Istanbul 6 October 2017, ESGAP course, Istanbul 1 2 Objectives What do we know? Invasive Candida and Aspergillosis Impact
More informationClinical, Cellular, and Molecular Factors That Contribute to Antifungal Drug Resistance
CLINICAL MICROBIOLOGY REVIEWS, Apr. 1998, p. 382 402 Vol. 11, No. 2 0893-8512/98/$04.00 0 Copyright 1998, American Society for Microbiology Clinical, Cellular, and Molecular Factors That Contribute to
More informationANTIMYCOTIC DRUGS Modes of Action
ANTIMYCOTIC DRUGS Modes of Action Prapasarakul Nuvee, D.V.M., Ph.D. Department of Veterinary Microbiology, Faculty of Veterinary Science, Chulalongkorn University 1 What drugs act as antifungal agents?
More informationAAC Accepts, published online ahead of print on 21 March 2011 Antimicrob. Agents Chemother. doi: /aac
AAC Accepts, published online ahead of print on 1 March 0 Antimicrob. Agents Chemother. doi:./aac.010- Copyright 0, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationNEW ANTI-INFECTIVE AGENTS IN 2003 : SPECTRUM AND INDICATIONS. 20th Symposium (spring 2003) Thursday May 22nd 2003
NEW ANTI-INFECTIVE AGENTS IN 2003 : SPECTRUM AND INDICATINS 20th Symposium (spring 2003) Thursday May 22nd 2003 The slides presented at this meeting are available on this site as "Web slide shows" and
More information(Notes on Anti-TB agents are included in the TB syllabus)
(Notes on Anti-TB agents are included in the TB syllabus) Antifungal Agents A. Zuger MD General background: 1. Fungi are eukaryotes, with more cellular similarities to human cells than to bacterial cells.
More informationEMERGING FUNGAL INFECTIONS IN IMMUNOCOMPROMISED PATIENTS
EMERGING FUNGAL INFECTIONS IN IMMUNOCOMPROMISED PATIENTS DR LOW CHIAN YONG MBBS, MRCP(UK), MMed(Int Med), FAMS Consultant, Dept of Infectious Diseases, SGH Introduction The incidence of invasive fungal
More informationEvidence-Based Approaches to the Safe and Effective Management of Invasive Fungal Infections. Presenter. Disclosures
Evidence-Based Approaches to the Safe and Effective Management of Invasive Fungal Infections Presenter James S. Lewis II, PharmD, FIDSA ID Clinical Pharmacy Coordinator Oregon Health and Science University
More informationReceived 5 August 2004/Accepted 26 September 2004
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 2005, p. 512 517 Vol. 49, No. 2 0066-4804/05/$08.00 0 doi:10.1128/aac.49.2.512 517.2005 Copyright 2005, American Society for Microbiology. All Rights Reserved.
More informationWHAT IS THE ROLE OF EMPIRIC TREATMENT FOR SUSPECTED INVASIVE CANDIDIASIS IN NONNEUTROPENIC PATIENTS IN THE ICU?
WHAT IS THE ROLE OF EMPIRIC TREATMENT FOR SUSPECTED INVASIVE CANDIDIASIS IN NONNEUTROPENIC PATIENTS IN THE ICU? Empiric antifungal therapy should be considered in critically ill patients with risk factors
More informationFungal Infection Pre-Infusion Data
Fungal Infection Pre-Infusion Data Registry Use Only Sequence Number: Date Received: CIBMTR Center Number: Event date: / / CIBMTR Form 2046 revision 5 (page 1 of 5). Last Updated May, 2018. Infection Episode
More informationCommon Fungi. Catherine Diamond MD MPH
Common Fungi Catherine Diamond MD MPH Birth Month and Day & Last Four Digits of Your Cell Phone # BEFORE: http://tinyurl.com/kvfy3ts AFTER: http://tinyurl.com/lc4dzwr Clinically Common Fungi Yeast Mold
More informationEmerging Fungal Diseases
INVITED ARTICLE EMERGING INFECTIONS Larry J. Strausbaugh, Section Editor Emerging Fungal Diseases Marcio Nucci 1 and Kieren A. Marr 2,3 1 University Hospital, Universidade Federal do Rio de Janeiro, Rio
More informationEfficacy of a Novel Echinocandin, CD101, in a Mouse Model of Azole-Resistant Disseminated Candidiasis
Efficacy of a Novel Echinocandin, CD0, in a Mouse Model of Azole-Resistant Disseminated Candidiasis L. Miesel, K-Y Lin, J. C. Chien, M. L. Hsieh, V. Ong, and K. Bartizal Eurofins Panlabs, Taipei, Taiwan
More informationAspergillosis in the critically ill patient
Aspergillosis in the critically ill patient José Artur Paiva Director of Emergency and Intensive Care Department Centro Hospitalar São João Porto Associate Professor of Medicine University of Porto Infection
More informationProphylaxis versus Diagnostics-driven approaches to treatment of Invasive fungal diseases. Y.L. Kwong Department of Medicine University of Hong Kong
Prophylaxis versus Diagnostics-driven approaches to treatment of Invasive fungal diseases Y.L. Kwong Department of Medicine University of Hong Kong Pathogenic yeast Candida Cryptococcus Trichosporon Pathogenic
More informationNational Center for Emerging and Zoonotic Infectious Diseases AR Lab Network Candida Testing
National Center for Emerging and Zoonotic Infectious Diseases AR Lab Network Candida Testing Snigdha Vallabhaneni, MD, MPH Medical Epidemiologist Centers for Disease Control and Prevention Invasive Candidiasis
More informationamphotericin B empiric therapy; preemptive therapy presumptive therapy Preemptive therapy Presumptive therapy ET targeted therapy ET
4 17 9 27 17 1 7 amphotericin B 34 empiric therapy; ET preemptive therapy presumptive therapy Preemptive therapy Presumptive therapy ET targeted therapy ET Key words: antifungal therapyempiric therapypreemptive
More information9/18/2018. Invasive Candidiasis. AR Lab Network Candida Testing. Most Common Healthcare Associated Bloodstream Infection in the United States?
National Center for Emerging and Zoonotic Infectious Diseases AR Lab Network Candida Testing Invasive Candidiasis Snigdha Vallabhaneni, MD, MPH Medical Epidemiologist Centers for Disease Control and Prevention
More informationVoriconazole Rationale for the EUCAST clinical breakpoints, version March 2010
Voriconazole Rationale for the EUCAST clinical breakpoints, version 2.0 20 March 2010 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised by the European
More informationAntifungal Update 2/24/11. Which is the most appropriate initial empirical therapy in a candidemic patient?
Antifungal Update B. Joseph Guglielmo, Pharm.D. Professor and Chair Department of Clinical Pharmacy School of Pharmacy University of California San Francisco The patient spikes a new fever and 3/3 blood
More informationTOWARDS PRE-EMPTIVE? TRADITIONAL DIAGNOSIS. GALACTOMANNAN Sensitivity 61% Specificity 93% Neg Predict Value >95% β-d-glucan Neg Predict Value 100% PCR
TOWARDS PRE-EMPTIVE? GALACTOMANNAN Sensitivity 61% Specificity 93% Neg Predict Value >95% TRADITIONAL DIAGNOSIS β-d-glucan Neg Predict Value 100% PCR diagnostics FUNGAL BURDEN FIRST TEST POSITIVE FOR ASPERGILLOSIS
More informationESCMID Online Lecture Library. by author
How To Best Use Antifungal Agents Cornelia Lass-Flörl Division of Hygiene and Medical Microbiology Innsbruck Medical University ESCMID SUMMER SCHOOL 2012 Epidemiology Diagnosis Roadmap Antifungal drugs
More informationEarly Diagnosis and Therapy for Fungal Infections
Early Diagnosis and Therapy for Fungal Infections Debra Goff PharmD, FCCP Clinical Associate Professor Infectious Disease Specialist The Ohio State University Medical Center Columbus Ohio, USA The Ohio
More informationAli Alabbadi. Sarah Jaar ... Nader
24 Ali Alabbadi Sarah Jaar... Nader Intro to Mycology *underlined text was explained in the lecture but is not found in the slides -mycology: the study of the mycoses of man (fungal infections) -less than
More informationAntifungal Agents. Polyenes Azoles Allyl and Benzyl Amines Other antifungals
OPTO 6434 General Pharmacology Antifungal Agents Dr. Alison McDermott Room 254 HBSB, Phone 713-743 1974 Email amcdermott@optometry.uh.edu Fall 2015 Reading: Chapter 50 Brody s Human Pharmacology by Wecker
More informationAntifungal drug resistance mechanisms in pathogenic fungi: from bench to bedside
REVIEW 10.1111/1469-0691.12495 Antifungal drug resistance mechanisms in pathogenic fungi: from bench to bedside M. Cuenca-Estrella National Center for Microbiology, Instituto de Salud Carlos III, Madrid,
More informationThe Evolving Role of Antifungal Susceptibility Testing. Gregory A. Eschenauer and Peggy L. Carver
S PECIAL A RTICLE The Evolving Role of Antifungal Susceptibility Testing Gregory A. Eschenauer and Peggy L. Carver Although increasing numbers of hospital microbiology laboratories are performing antifungal
More information